Monday, February 27, 2012
Wednesday, February 22, 2012
Tuesday, February 14, 2012
OncoSec Initiates Phase II Merkel Cell Carcinoma Study and Doses Several Patients
Feb 13, 2012
AN DIEGO, Feb. 13, 2012 /PRNewswire via COMTEX/ -- OncoSec Medical Incorporated,ONCS +2.86% which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC). The clinical trial is designed to test DNA IL-12 administered using OncoSec's novel treatment approach for immunotherapy (referred to as OMS ElectroImmunotherapy), in patients with local and distant Merkel cell carcinoma.
A total of up to 15 patients with local and distant Merkel cell carcinoma will be enrolled in this Phase II, single-arm, open-label, multi-center study. The trial is designed to assess the clinical and biologic effects of increased local expression of IL-12 protein in the tumor microenvironment following treatment with OMS ElectroImmunotherapy. It is anticipated that marked local expression of IL-12 in the tumor will induce an immunologic response in the tumor microenvironment, which may result in clinical benefit for the patient. Investigators at the University of Washington, a world leader in the treatment of Merkel cell carcinoma, have received Investigational Review Board (IRB) approval and will continue recruitment for this clinical trial as the lead enrollment center. Several patients have been enrolled with the first patient successfully completing treatment on January 6, 2012.
Rising incidence of .